Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: the case of simvastatin and cholestyramine in The Netherlands

The American Journal of Cardiology
L L MartensC A Ascoop

Abstract

To assess the cost-effectiveness of cholesterol-reducing therapy with cholestyramine and simvastatin in the primary prevention of coronary artery disease in The Netherlands, a model of coronary artery disease incidence was used based on multivariate logistic risk functions from the Framingham study. For men with initial cholesterol levels of 8 mmol/liter, the cost per year of life saved of cholestyramine, expressed in Dutch guilders (NLG; 1 NLG = $0.50), ranges from approximately NLG 208,000 to NLG 483,000, depending on the patient's age at initiation of therapy. For simvastatin, cost-effectiveness ranges from NLG 46,000 to NLG 98,000 per year of life saved among this group of men. Similar differences between simvastatin and cholestyramine therapy prevail among women, although the costs per year of life saved for both agents are considerably higher. These results suggest that (1) simvastatin is substantially more cost effective than is cholestyramine; (2) simvastatin therapy compares favorably with other generally accepted medical practices, especially if treatment is initiated at an early age; and (3) as its long-term safety record becomes more established, simvastatin may become accepted as a drug of first choice in the treat...Continue Reading

Citations

May 1, 1996·Social Science & Medicine·E Rieger
Feb 1, 1996·Cardiology Clinics·T A Pearson, H J Swan
Aug 1, 1993·Australian and New Zealand Journal of Medicine·C J LintottJ Bremer
Jul 1, 1991·American Journal of Public Health·T W Kelsey, P L Jenkins
Aug 30, 2003·Acta Clinica Belgica·D Devroey, W Betz
Dec 15, 1991·The American Journal of Cardiology·J A Mauskopf, T L Wenger
Apr 5, 2012·Medical Decision Making : an International Journal of the Society for Medical Decision Making·Bob J H van KempenM G Myriam Hunink
Mar 6, 2007·PharmacoEconomics·Pearl D GumbsOlaf H Klungel
Oct 1, 1999·Environmental Health and Preventive Medicine·N NakanishiK Tatara
May 13, 1999·Journal of Epidemiology and Community Health·T van der WeijdenR P Grol
Oct 1, 1991·Medical Informatics = Médecine Et Informatique·M JohannessonB Jönsson
Sep 5, 1994·PharmacoEconomics·A Pelc
Sep 4, 1997·Journal of Health Services Research & Policy·S MorrisD Pettitt
Dec 8, 1996·Journal of Health Services Research & Policy·M SculpherM Buxton

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.